Evidence, values, and funding decisions in Canadian cancer systems. Issue 6 (November 2019)

• Record Type: Journal Article
• Authors: Peacock, Stuart J.; Regier, Dean A.; Raymakers, Adam J. N.; Chan, Kelvin K. W.
• Is Part Of: Healthcare management forum. Volume 32:Issue 6(2019)
• Page Start: 293
• Page End: 298
• Publication Date: 2019-11
• Subjects: Health services administration -- Periodicals; Health services administration -- Canada -- Periodicals; 362.1068
• DOI: 10.1177/0840470419870831
• Languages: English
• ISSNs: 0840-4704

Abstract

Expenditure on cancer therapies is rising rapidly in many countries, particularly for cancer drugs. In recent years, this has stimulated a global debate among the public, patients, clinicians, decision-makers, and the pharmaceutical industry on value, affordability, and sustainability propositions relating to cancer therapies. In this article, we discuss some recent developments in evidence-based approaches to priority setting and resource allocation in Canadian cancer systems. These developments include new methods for deliberative public engagement, generating and using real-world evidence, multi-criteria decision analysis, and handling uncertainty with evidence for gene therapies.